In a landmark decision that addresses a long-standing therapeutic void in pediatric medicine, the U.S. Food and Drug Administration (FDA) has granted approval for ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 in newborns. This regulatory milestone permits the use of the medication in pediatric patients weighing as little as 2 kg (approximately 4.4 pounds), effectively eliminating the minimum-age requirement that previously restricted access for the most vulnerable infants.
This approval represents a significant shift in the landscape of perinatal HIV management. By lowering the weight threshold and removing age barriers, clinicians now have access to a second-generation integrase strand transfer inhibitor (INSTI) tailored specifically to the physiological needs of neonates. As global health organizations continue to push for the elimination of mother-to-child HIV transmission, this development provides a critical tool for medical providers tasked with protecting the lives of newborns exposed to the virus.
The Evolution of Tivicay: A Chronology of Pediatric Expansion
The journey to this approval has been a multi-year effort to refine pediatric formulations and establish safety profiles for the youngest patients. The history of Tivicay reflects the broader pharmaceutical commitment to closing the "treatment gap" for children.
- August 2013: The FDA granted initial approval for Tivicay (dolutegravir) to treat HIV-1 infection in adults and adolescents aged 12 or older who weighed at least 40 kg (88.2 pounds).
- 2020: Recognizing the need for age-appropriate delivery methods, the FDA approved the dispersible tablet formulation, Tivicay PD. This version was initially authorized for patients at least four weeks old and weighing at least 3 kg (6.6 pounds).
- 2025 (CROI): Preliminary results from the IMPAACT 2023 study were presented at the Conference on Retroviruses and Opportunistic Infections (CROI). These data provided the foundational evidence regarding chronic dosing in infants as young as five days old.
- August 2026: The FDA officially expanded the indication for Tivicay PD, clearing it for use in newborns from birth, provided they meet the minimum weight requirement of 2 kg.
This progression underscores a strategic pivot in clinical research: moving away from "adult-centric" dosing toward rigorous, age-stratified studies that account for the unique metabolic and pharmacokinetic profiles of newborns.
Supporting Data: The IMPAACT 2023 Study
The regulatory approval was not reached in a vacuum; it was predicated on the robust findings of the NIH-funded IMPAACT 2023 study. This multicenter, phase 1 trial was meticulously designed to establish the safety, tolerability, and pharmacokinetic (PK) properties of dolutegravir in the critical first six weeks of life.
The study enrolled 48 mother-infant pairs across clinical sites in the United States, Thailand, and South Africa. The diversity of the cohort was essential for ensuring that the findings were applicable to a global population. Infants were administered Tivicay PD starting from birth, alongside standard-of-care antiretroviral (ARV) regimens intended to prevent mother-to-child transmission.
Pharmacokinetics and Safety Outcomes
The FDA’s review of the IMPAACT 2023 data revealed that the drug levels achieved in these newborns were consistent with adult exposures—the "gold standard" for ensuring therapeutic efficacy. Perhaps most importantly, the safety profile observed in the 48 infants was comparable to that of older children and adults, with no unexpected adverse events reported.
A specific sub-cohort of 15 infants provided the most granular data regarding chronic, long-term dosing. These infants, weighing between 2.3 and 3.6 kg, began treatment within the first five days of life. The regimen involved a 5-mg dispersible tablet administered every other day for the first two weeks, transitioning to daily dosing thereafter. The success of this regimen in maintaining viral suppression while managing drug toxicity levels was the final piece of evidence required for the FDA’s positive determination.
Perspectives from the Clinical Community
The medical community has hailed this approval as a vital advancement. Diana F. Clarke, Pharm.D., a professor at the Boston University School of Medicine and the lead investigator of the IMPAACT 2023 study, emphasized the gravity of the announcement in a formal statement.
"For too long, newborns living with HIV have had too few treatment options designed and studied to meet their unique needs, despite the importance of starting treatment as early as possible," Dr. Clarke remarked. Her sentiment reflects a consensus among pediatric infectious disease specialists who have long struggled with the lack of pediatric-specific ARV options. By validating the use of an INSTI—a class of drugs known for high barriers to resistance and favorable tolerability—the FDA has provided clinicians with a potent new weapon to combat early-life HIV progression.
The Global and Domestic Landscape of Pediatric HIV
While perinatal HIV transmission is a public health crisis in many developing nations, the United States has made significant strides in prevention. Current estimates indicate that fewer than 50 infants are born with HIV in the U.S. annually, with the risk of perinatal transmission reduced to 1% or less through rigorous prenatal and postnatal care.
However, the global stakes remain high. UNICEF reports that approximately 50% of infants living with HIV will die before their second birthday if they do not receive timely and effective antiretroviral therapy. Therefore, while the U.S. market for this drug may be small, the global implications of a standardized, safe, and effective pediatric regimen are profound. The ability to treat infants from birth—rather than waiting for a month of development—drastically improves the prognosis for those living in high-prevalence areas where the virus can cause rapid, often fatal, disease progression.
Commercial Implications for ViiV and GSK
From a market perspective, the approval of Tivicay PD represents a targeted expansion within a larger, shifting portfolio. The standalone Tivicay brand has seen a plateau in recent financial quarters. GSK, the parent company of ViiV Healthcare, reported 2025 sales for the Tivicay brand at £1.323 billion, a slight decline from the previous year. First-half 2026 results showed a continued, albeit moderate, downward trend of 3% on a reported basis.
However, this decline in older, single-drug products is being strategically offset by the company’s newer, long-acting, and combination therapies. GSK’s total HIV portfolio grew by 11% in 2025, reaching £7.687 billion. The growth is primarily fueled by the success of Dovato and long-acting injectables like Cabenuva and Apretude.
The expansion of the Tivicay PD label serves a dual purpose: it maintains the relevance of the dolutegravir molecule within the pediatric space while cementing ViiV’s leadership in the HIV market. By securing approval for the most difficult-to-treat patient population, ViiV not only fulfills a moral imperative but also secures a long-term position in the pediatric HIV care continuum.
Future Outlook: Implications for Pediatric Care
The implications of this FDA decision extend far beyond the immediate approval of a single medication. It establishes a new template for drug development in neonatology. By utilizing pharmacokinetic modeling and multicenter international trials, researchers have demonstrated that it is possible to bridge the gap between adult clinical data and neonatal reality without compromising safety.
Moving forward, the focus will likely shift toward the global rollout of these findings and the integration of the 5-mg dispersible tablet into international pediatric treatment guidelines. As HIV research moves closer to "functional cures" and better long-term management, the ability to initiate high-efficacy treatment on day one of life will remain a foundational pillar of pediatric care.
The approval of Tivicay PD is not merely a bureaucratic victory; it is a clinical triumph that promises to reduce mortality, minimize long-term viral damage, and offer a brighter future for infants born with HIV. As we look toward the next decade of infectious disease management, the integration of such precise, evidence-based therapies will be essential to ensuring that no child is left behind in the global effort to end the HIV epidemic.
About the Author
